More than 2 years after the ugly roci debacle, Clovis says that the SEC is prepping civil charges
The hot water that Clovis $CLVS has been in with the SEC for the past two years is beginning to boil.
The biotech today alerted investors that the SEC has filed a Wells Notice, signaling its intention to bring civil actions against current and former execs at the cancer drug biotech. The SEC filing did not specify what actions it will face, but Clovis did say it plans to contest any charges.
Clovis’ 10-K has spotlighted an ongoing investigation by the SEC and the Justice Department into an ugly incident in late 2015 centered on their now defunct lung cancer drug rociletinib, saying it was cooperating with the feds on their probe.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.